Artificial Intelligence as a Multifaceted Toolkit for Antibacterial Drug Discovery against Resistance
Research · 01.01.2026 · 9
DOI: 10.34133/research.1457 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Research, online erschienen am 10.11.2026. Verfasst von Jifeng You und 11 weiteren Autor:innen. Beteiligte Einrichtung: The Third Affiliated Hospital, School of Medicine, Foshan University, Foshan, Guangdong, China. Die Arbeit nennt 193 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, Special Fund Project for Science and Technology Innovation Strategy of Guangdong Province.
Abstract (Originalsprache)
How artificial intelligence (AI) can be rationally applied to antibacterial drug discovery and development to overcome antimicrobial resistance (AMR) remains insufficiently defined, particularly across different resistance mechanisms and translational stages. The global emergence and dissemination of AMR are compromising conventional antibacterial therapies, while slow antibiotic discovery, limited target diversity, and reliance on single-mechanism drug design further increase the risk of inadequate treatment options. With strengths in multi-omics integration, complex pattern recognition, and structure-guided molecular design, AI offers a promising approach to support next-generation antibacterial development. This review focuses on AI-related strategies for antimicrobial development against bacterial resistance and provides a systematic overview of advances in target identification, molecular design, activity prediction, and clinical translation. Rather than proposing a new theoretical framework, the review introduces a pragmatic synthesis tool for evaluating where AI adds value and where important limitations remain, considering application objectives, data properties, validation depth, biological interpretability, and translational feasibility. Major challenges are highlighted, including data heterogeneity, clonal bias, limited external validation, discrepancies between in vitro activity and in vivo therapeutic efficacy, and the absence of regulatory approval for any AI-discovered or AI-designed antibacterial agent. Correspondingly, future directions are delineated, including multimodal data integration, explainable AI methodologies, validation through synthetic biology, and coordinated international regulatory efforts. Overall, this review provides a structured overview of how AI can be integrated with rational antibacterial design while considering both its potential and current limitations for addressing multidrug-resistant pathogens.
Autor:innen und Institutionen
- The Third Affiliated Hospital, School of Medicine, Foshan University, Foshan, Guangdong, China.
- Foshan Key Laboratory for Drug Screening, Diagnosis, and Treatment of Bacterial and Biofilm Infections, Foshan, Guangdong, China.
- School of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- Unit of Pharmaco-Therapy, -Epidemiology and -Economics (PTEE), Department of Pharmacy, University of Groningen, Groningen, the Netherlands.
- State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Pharmacy, Jinan Univer…
ORCID-Profile: Chao Lu, Jialiang Guo
Förderung
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
- Special Fund Project for Science and Technology Innovation Strategy of Guangdong Province
Zitieren
APA
You, J., Xu, S., Luo, B., He, S., Yang, Z., Liu, Z., Wang, Y., Wu, M., Zhou, G., Zhao, M., Lu, C., & Guo, J. (2026). Artificial Intelligence as a Multifaceted Toolkit for Antibacterial Drug Discovery against Resistance. Research, 9. https://doi.org/10.34133/research.1457
Vancouver
You J, Xu S, Luo B, He S, Yang Z, Liu Z, et al. Artificial Intelligence as a Multifaceted Toolkit for Antibacterial Drug Discovery against Resistance. Research. 2026;9. doi:10.34133/research.1457
BibTeX
@article{You2026,
author = {You, Jifeng and Xu, Shixiang and Luo, Baozhang and He, Shiwei and Yang, Zhihui and Liu, Zheng and Wang, Yuanyuan and Wu, Minghe and Zhou, Guiling and Zhao, Mingming and Lu, Chao and Guo, Jialiang},
title = {Artificial Intelligence as a Multifaceted Toolkit for Antibacterial Drug Discovery against Resistance},
journal = {Research},
year = {2026},
volume = {9},
doi = {10.34133/research.1457}
}
EUVIMED